Trials / Completed
CompletedNCT00617994
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
An Open Label, Safety, Tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD) and Preliminary Efficacy Study of Ruxolitinib When Applied to Patients With Plaque Psoriasis Involving 2 - 20% Body Surface Area (BSA).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Ruxolitinib 1.5% cream BID for 28 days |
Timeline
- Start date
- 2007-08-31
- Primary completion
- 2009-04-30
- Completion
- 2009-05-31
- First posted
- 2008-02-18
- Last updated
- 2022-02-08
- Results posted
- 2022-02-08
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00617994. Inclusion in this directory is not an endorsement.